Rhumbline Advisers Alpine Immune Sciences, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$17.75 - $41.6 $192,090 - $450,195	10,822 Added 24.75%	54,543 $2.16 Million
Q4 2023 Feb 08, 2024	BUY	$8.54 - $20.22 $19,795 - $46,869	2,318 Added 5.6%	43,721 $833,000
Q3 2023 Nov 09, 2023	BUY	$10.13 - $13.98 $20,027 - $27,638	1,977 Added 5.01%	41,403 $474,000
Q2 2023 Aug 08, 2023	BUY	$6.84 - $11.91 $44,993 - $78,343	6,578 Added 20.03%	39,426 $405,000
Q1 2023 May 11, 2023	BUY	$7.0 - $8.75 $46,305 - $57,881	6,615 Added 25.22%	32,848 $254,000
Q4 2022 Feb 14, 2023	BUY	$5.45 - $7.35 $24,503 - $33,045	4,496 Added 20.68%	26,233 $193,000
Q3 2022 Nov 10, 2022	BUY	$6.89 - $9.39 $9,184 - $12,516	1,333 Added 6.53%	21,737 $157,000
Q2 2022 Aug 11, 2022	BUY	$6.71 - $9.52 $136,910 - $194,246	20,404 New	20,404 $174,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.